The Impact of Covid-19 Outbreak among Lymphoma Patients: What Did We Learn?

Piero Maria Stefani, F. Cinetto, R. Scarpa, E. Mauro, C. Agostini, M. Rattazzi
{"title":"The Impact of Covid-19 Outbreak among Lymphoma Patients: What Did We Learn?","authors":"Piero Maria Stefani, F. Cinetto, R. Scarpa, E. Mauro, C. Agostini, M. Rattazzi","doi":"10.26502/jcsct.5079161","DOIUrl":null,"url":null,"abstract":"The Impact of Covid-19 Outbreak among Lymphoma Patients: What Did We Learn? Journal Clinical Therapeutics (2022): Abstract A very high number of articles have been published regarding SARSCOVID-19 infection among oncohematology patients. However, outside epidemiologic data and guidelines regarding the management of SARSCOVID-19 disease, no shared recommendations or expert opinions are available to decide whether it is advisable to initiate antineoplastic therapy during a phase of pandemic and, if so, how to modulate the treatment schedule. The need to administer antineoplastic or biological drugs and available monoclonal antibodies licensed for lymphoproliferative diseases makes it particularly complex in this perspective to define reasoned, evidence-based choices. We reviewed published studies with the largest cohort of patients, intending to recognize the most relevant risk factors. We have highlighted some unresolved questions about immunologic perturbation during SARSCOVID-19 infection that hinder a defined and biologically oriented approach, especially in the case of immunosuppression, both primary and acquired. It is interesting, in this context, that preliminary evidence shows a characteristic clinical course of SARSCOVID-19 infection that suggests specific management. We also summarized the role of immunoglobulin replacement treatment or monoclonal antibody administration.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer science and clinical therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/jcsct.5079161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The Impact of Covid-19 Outbreak among Lymphoma Patients: What Did We Learn? Journal Clinical Therapeutics (2022): Abstract A very high number of articles have been published regarding SARSCOVID-19 infection among oncohematology patients. However, outside epidemiologic data and guidelines regarding the management of SARSCOVID-19 disease, no shared recommendations or expert opinions are available to decide whether it is advisable to initiate antineoplastic therapy during a phase of pandemic and, if so, how to modulate the treatment schedule. The need to administer antineoplastic or biological drugs and available monoclonal antibodies licensed for lymphoproliferative diseases makes it particularly complex in this perspective to define reasoned, evidence-based choices. We reviewed published studies with the largest cohort of patients, intending to recognize the most relevant risk factors. We have highlighted some unresolved questions about immunologic perturbation during SARSCOVID-19 infection that hinder a defined and biologically oriented approach, especially in the case of immunosuppression, both primary and acquired. It is interesting, in this context, that preliminary evidence shows a characteristic clinical course of SARSCOVID-19 infection that suggests specific management. We also summarized the role of immunoglobulin replacement treatment or monoclonal antibody administration.
Covid-19疫情对淋巴瘤患者的影响:我们学到了什么?
Covid-19疫情对淋巴瘤患者的影响:我们学到了什么?Journal Clinical Therapeutics(2022):摘要关于血液肿瘤患者中SARSCOVID-19感染的文章已经发表了非常多的文章。然而,除了关于sars -19疾病管理的流行病学数据和指南之外,没有共同的建议或专家意见来决定是否建议在大流行阶段开始抗肿瘤治疗,如果是,如何调整治疗计划。由于需要使用抗肿瘤药物或生物药物以及获得许可用于淋巴增生性疾病的现有单克隆抗体,因此从这一角度确定合理的、基于证据的选择尤为复杂。我们回顾了已发表的最大患者队列研究,旨在识别最相关的危险因素。我们强调了一些未解决的关于sarscov -19感染期间免疫扰动的问题,这些问题阻碍了明确的和生物学导向的方法,特别是在原发性和获得性免疫抑制的情况下。在此背景下,有趣的是,初步证据显示sars -19感染具有特征性的临床病程,建议采用特定的治疗方法。我们还总结了免疫球蛋白替代治疗或单克隆抗体治疗的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信